Salah-Eddin Al-Batran, MD, on Gastric and GEJ Adenocarcinoma: Results From the FAST Trial

2016 ASCO Annual Meeting
Tweet this page

Salah-Eddin Al-Batran, MD, of the Institute of Clinical Cancer Research and Nordwest Hospital, discusses findings from this international phase II study of epirubicin, oxaliplatin, and capecitabine with or without IMAB362, as first-line treatment of gastric and gastroesophageal junction adenocarcinoma (Abstract LBA4001).

Advertisement

Advertisement



Advertisement

click me